Copyright © 2004 by the European Society of Cardiology.
Clinical research
Statin therapy improves cardiovascular outcome of patients with peripheral artery disease
a Division of Angiology, Department of Internal Medicine II, Vienna General Hospital, Medical School, Waehringer Guertel 18-20, A-1090 Vienna, Austria
b Laboratory, Vienna General Hospital, Medical School, Waehringer Guertel 18-20, A-1090 Vienna, Austria
c Emergency Medicine, Vienna General Hospital, Medical School, Waehringer Guertel 18-20, A-1090 Vienna, Austria
Received August 5, 2003;
revised February 2, 2004;
accepted February 13, 2004
* Corresponding author. Tel.: +43-1-40400-4670; fax: +43-1-40400-4665
E-mail address: martin.schillinger{at}akh-wien.ac.at
See page 712 for the editorial comment on this article1
Aims We sought to examine the interrelationship between statin use, inflammation, and outcome of high-risk patients with advanced atherosclerosis.
Methods and results We prospectively studied 515 patients with severe peripheral artery disease (median age 70 years, 296 males). The cardiovascular risk profile and laboratory parameters of inflammation (high-sensitivity C-reactive protein [hs-CRP], serum amyloid A [SAA], fibrinogen, serum albumin, neutrophil counts) were obtained, and patients were followed for a median of 21 months (interquartile range 12–25) for the occurrence of myocardial infarction (MI) and death. We observed 19 MIs (5 fatal and 14 nonfatal) and 65 deaths. Cumulative survival and event-free survival rates (freedom from death and MI) at 6, 12, and 24 months were 97%, 95%, and 89%, and 96%, 93% and 87%, respectively. Patients receiving statin therapy (
, 52%) had a lower level of inflammation (hs-CRP 
, SAA 
, fibrinogen 
, albumin , neutrophils 
) and better survival (adjusted hazard ratio [HR] 0.52, 
) and event-free survival rates (adjusted HR 0.48, 
) than patients not treated with statins. However, patients with low inflammatory activity (hs-CRP 
0.42 mg/dl) had no significant benefit from statin therapy (
for survival; 
for event-free survival), whereas in patients with high hs-CRP (>0.42 mg/dl) statin therapy was associated with a significantly reduced risk for mortality (adjusted HR 0.58, 
) and the composite of myocardial infarction and death (adjusted HR 0.46, 
).
Conclusion Statin therapy is associated with a substantially improved intermediate-term survival of patients with severe peripheral artery disease and a high inflammatory activity, whereas in patients with low hs-CRP no survival benefit was observed.
Key Words: Statins • Mortality • Inflammation • Peripheral vascular disease
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Statins in patients at high risk of cardiovascular disease presenting with peripheral artery disease
- B Boland and G Goderis
EHJ 2004 25: 712-713.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  K. I. Paraskevas, N. Bessias, T. T. Papas, V. Andrikopoulos, and D. P. Mikhailidis Is High-sensitivity C-reactive Protein Associated With Subclinical Peripheral Atherosclerosis? Angiology, February 1, 2009; 60(1): 8 - 11. [PDF]
|
|
|
|
 |
|
 S. Sabeti, O. Schlager, M. Exner, W. Mlekusch, J. Amighi, P. Dick, G. Maurer, K. Huber, R. Koppensteiner, O. Wagner, et al. Progression of Carotid Stenosis Detected by Duplex Ultrasonography Predicts Adverse Outcomes in Cardiovascular High-Risk Patients Stroke, November 1, 2007; 38(11): 2887 - 2894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Schofield, G. Libby, G. M. Brennan, R. R. MacAlpine, A. D. Morris, G. P. Leese, and for the DARTS/MEMO Collaboration Mortality and Hospitalization in Patients After Amputation: A comparison between patients with and without diabetes Diabetes Care, October 1, 2006; 29(10): 2252 - 2256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Aboyans, M. H. Criqui, J. O. Denenberg, J. D. Knoke, P. M Ridker, and A. Fronek Risk Factors for Progression of Peripheral Arterial Disease in Large and Small Vessels Circulation, June 6, 2006; 113(22): 2623 - 2629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H.H. Feringa, V. H. van Waning, J. J. Bax, A. Elhendy, E. Boersma, O. Schouten, W. Galal, R. V. Vidakovic, M. J. Tangelder, and D. Poldermans Cardioprotective Medication Is Associated With Improved Survival in Patients With Peripheral Arterial Disease J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1182 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Youssef, P. Gupta, D. P. Mikhailidis, and G. Hamilton Risk Modification in Patients with Peripheral Arterial Disease: A Retrospective Survey Angiology, May 1, 2005; 56(3): 279 - 287. [Abstract] [PDF]
|
|
|
|
 |
|
 S. S. Daskalopoulou, V. G. Athyros, G. Hamilton, and D. P. Mikhailidis Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2005; 10(2): 145 - 147. [PDF]
|
|
|
|
 |
|
 B Boland and G Goderis Statins in patients at high risk of cardiovascular disease presenting with peripheral artery disease Eur. Heart J., May 1, 2004; 25(9): 712 - 713. [Full Text] [PDF]
|
|